Nonviral gene delivery vectors for transfection of the CAR gene for CAR-T cell therapy

The introduction of the CAR gene via retrovirus is the most widely used and most successful technique for CAR-T cell therapy. However, the limitations and risks associated with viral gene therapy continue to motivate the development of nonviral gene delivery technologies that are potentially safer, less expensive, and quicker. In terms of safety and efficacy, electroporation has emerged as the most promising non-viral technology, albeit more optimization testing and clinical trials are required before it can be directly compared to retroviral CAR gene delivery techniques. But these findings suggest that non-viral gene delivery to T cells (and other related cells, such as natural killer cells) is feasible and is quickly emerging as a viable alternative to CAR-T cell therapy and other gene therapies.